IP And Access Can Co-exist: Indian Pharma Alliance
This article was originally published in PharmAsia News
Executive Summary
An out-of-the-box deal has raised hopes that multinational companies and Indian generic makers can work in tandem for better access to medicines. That’s the essence of Gilead’s multiple partnering deals in India as described by the Indian Pharmaceutical Alliance – a lobby that has resisted pressures from MNCs seeking a tighter intellectual property framework in India.